As noted earlier, Argus analyst Kevin Heal initiated Nasdaq with a Buy rating and a price target of $97, citing the company's latest Q4 results that showed an 11% growth in organic revenue and a 21% growth in EPS driven by "equity market volatility and gains in its nontrading businesses." The analyst expects Nasdaq to benefit from the "secular trends in its core data and listings business, including increased demand for real-time data and analytics, the growing popularity of passive index investing, and the need for greater price transparency." Heal further expects investor focus to remain on the company's "strong trading volumes".